3D human bone marrow stromal and endothelial cell spheres promote bone healing in an osteogenic niche.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 8 11 2018
medline: 19 11 2019
entrez: 8 11 2018
Statut: ppublish

Résumé

The current study used an ex vivo [embryonic day (E)18] chick femur defect model to examine the bone regenerative capacity of implanted 3-dimensional (3D) skeletal-endothelial cell constructs. Human bone marrow stromal cell (HBMSC) and HUVEC spheroids were implanted within a bone defect site to determine the osteogenic potential of the skeletal-endothelial cell unit. Cells were pelleted as co- or monocell spheroids and placed within 1-mm-drill defects in the mid-diaphysis of E18 chick femurs and cultured organotypically for 10 d. Micro-computed tomography analysis revealed significantly ( P = 0.0001) increased levels of bone volume (BV) and BV/tissue volume ratio in all cell-pellet groups compared with the sham defect group. The highest increase was seen in BV in femurs containing the HUVEC and HBMSC monocell constructs. Type II collagen expression was particularly pronounced within the cell spheres containing HBMSCs and HUVECs, and CD31-positive cell clusters were prominent within HUVEC-implanted defects. These studies demonstrate the importance of the 3D osteogenic-endothelial niche interaction in bone regeneration. Elucidating the component cell interactions in the osteogenic-vascular niche and the role of exogenous factors in driving these osteogenic processes will aid the development of better bone reparative strategies.-Inglis, S., Kanczler, J. M., Oreffo, R. O. C. 3D human bone marrow stromal and endothelial cell spheres promote bone healing in an osteogenic niche.

Identifiants

pubmed: 30403537
doi: 10.1096/fj.201801114R
pmc: PMC6404559
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3279-3290

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/G010579/1
Pays : United Kingdom

Références

Eur Cell Mater. 2010 Sep 06;20:149-61
pubmed: 20818597
PLoS One. 2015 Jun 05;10(6):e0129266
pubmed: 26047122
Front Biosci. 1999 Oct 15;4:D731-42
pubmed: 10525482
J Orthop Trauma. 2005 Nov-Dec;19(10 Suppl):S4-6
pubmed: 16479221
Cell Prolif. 2009 Aug;42(4):498-505
pubmed: 19489982
Microvasc Res. 2015 Mar;98:40-7
pubmed: 25497270
Blood. 2008 Aug 15;112(4):957-64
pubmed: 18344423
Bone. 2002 May;30(5):718-25
pubmed: 11996910
Eur Cell Mater. 2008 May 02;15:100-14
pubmed: 18454418
FASEB J. 2001 Feb;15(2):447-57
pubmed: 11156960
Eur Cell Mater. 2011 Oct 19;22:242-57; discussion 257
pubmed: 22012735
Stem Cell Res. 2011 May;6(3):238-50
pubmed: 21420373
Tissue Eng Part A. 2015 Apr;21(7-8):1320-32
pubmed: 25588588
Stem Cell Reports. 2016 Jun 14;6(6):897-913
pubmed: 27304917
Tissue Eng Part C Methods. 2017 Apr;23(4):200-218
pubmed: 28406754
Stem Cell Res Ther. 2015 Nov 05;6:218
pubmed: 26541817
J Cell Biol. 1998 Nov 30;143(5):1341-52
pubmed: 9832561
Injury. 2011 Jun;42(6):551-5
pubmed: 21489527
J Cell Mol Med. 2011 Jun;15(6):1266-86
pubmed: 21251219
Stem Cell Res Ther. 2016 Jan 18;7:13
pubmed: 26781715
Sci Rep. 2017 Jul 31;7(1):6859
pubmed: 28761088
Eur Cell Mater. 2011 Jun 20;21:558-67
pubmed: 21710446
J Clin Invest. 1973 Nov;52(11):2745-56
pubmed: 4355998
Nature. 2014 Mar 20;507(7492):323-328
pubmed: 24646994
Eur Cell Mater. 2013 Nov 06;26:222-33
pubmed: 24197544
Nat Cell Biol. 2017 Mar;19(3):189-201
pubmed: 28218908
Cell Transplant. 2006;15(6):521-32
pubmed: 17121163
Tissue Eng Part A. 2012 Dec;18(23-24):2395-405
pubmed: 22731749
Biomaterials. 1998 Oct;19(20):1845-54
pubmed: 9855185
Braz J Med Biol Res. 2005 Oct;38(10):1455-62
pubmed: 16172738
Tissue Eng Part A. 2015 Feb;21(3-4):530-40
pubmed: 25228401
Connect Tissue Res. 1989;20(1-4):65-71
pubmed: 2692958
Eur Cell Mater. 2014 Feb 19;27:137-48; discussion 148
pubmed: 24554271
Mater Sci Eng C Mater Biol Appl. 2017 Apr 1;73:310-318
pubmed: 28183614
Biofabrication. 2017 Sep 11;9(4):045005
pubmed: 28837043
Drug Discov Today. 2003 Nov 1;8(21):980-9
pubmed: 14643161

Auteurs

Stefanie Inglis (S)

Bone and Joint Research Group, Centre for Human Development, Stem Cells, and Regeneration, Institute of Developmental Sciences, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.

Janos M Kanczler (JM)

Bone and Joint Research Group, Centre for Human Development, Stem Cells, and Regeneration, Institute of Developmental Sciences, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.

Richard O C Oreffo (ROC)

Bone and Joint Research Group, Centre for Human Development, Stem Cells, and Regeneration, Institute of Developmental Sciences, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH